Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy

Journal of Rheumatology

Volumn 35, Issue 2, 2008, Pages 310-314

  Briot, Karine ^a,c   Roux, Christian ^a   Gossec, Laure ^a   Charni, Nadine ^b   Kolta, Sami ^a   Dougados, Maxime ^a   Garnero, Patrick ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c Cochin Hospital ^*  (France)

Author keywords

Cartilage metabolism; Collagen synthesis; Etanercept; Spondyloarthropathy

Indexed keywords

BIOCHEMICAL MARKER; C TERMINAL PROPEPTIDE OF TYPE 2 COLLAGEN; COLLAGEN TYPE 2; ETANERCEPT; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARTILAGE DEGENERATION; CARTILAGE METABOLISM; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; FEMALE; FRIEDMAN TEST; HUMAN; MALE; METABOLISM; PRIORITY JOURNAL; SPONDYLOARTHROPATHY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; CARTILAGE; COLLAGEN TYPE II; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROCOLLAGEN; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES;

EID: 39549096047     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Francois RJ, Eulderink F, Bywaters EGL. Commented glossary for rheumatic spinal diseases, based on pathology. Ann Rheum Dis 1995;54:615-25.
2. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis: the Heberden Oration 1970. Ann Rheum Dis 1971;30:213-23.
3. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicenter trial. Lancet 2002;359:1187-93.
4. Gorman JD, Sack KE, Davis JC. A randomized, double blind, placebo-controlled trial of etanercept in the treatment of ankylosing spondylitis. N Engl J Med 2002;346:1349-56.
5. Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double blind, placebo controlled trial. Arthritis Rheum 2006;54:2136-46.
6. Dougados M, Geguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 1999;26:971-4.
7. MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI). A new validated approach to disease assessment. Arthritis Rheum 1998;41:2263-70.
8. Dawes PT. Stoke Ankylosing Spondylitis Spine Score. J Rheumatol 1999;26:993-6.
9. Spoorenberg A, de Vlam K, van der Linden S, et al. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 2004;31:125-32.
10. Kojima T, Mwale F, Yasuda T, et al. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001;44:120-7.
11. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
12. Heinegard D, Bayliss M, Lorenzo P. Biochemistry and metabolism of normal and osteoarthritic cartilage. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 1998:75-84.
13. Garnero P, Geusens P, Landewe R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S54-S58.
14. Garnero P, Landewe R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:2847-56.
15. Landewe R, Geusens P, Boers M, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;5:1390-9.
16. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of cartilage proteoglycan aggrecan: implications for pathogenesis. J Clin Invest 1994;94:25-33.
17. Garnero P, Ayral X, Rousseau JC, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
18. Reijman M, Hazes JM, Bierma-Zienstra MA, et al. Predictive value of a cartilage degradation marker for radiologic osteoarthritis: the Rotterdam Study. Arthritis Rheum 2004;50:2471-8.
19. Mazieres B, Garnero P, Gueguen A, et al. Molecular markers of cartilage breakdown and synovitis are strong independent predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 2006;65:354-9.
20. Kim TH, Stone M, Payne U, et al. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005;52:885-91.
21. Maksymowych WP, Poole AR, Hieben L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005;32:1911-7.
22. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
23. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by the collagenases. J Immunol Methods 2004;294:145-53.
24. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (Helix II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005;52:1081-90.
25. Charni N, Juillet F, Garnero P. A novel serum ELISA for II collagen helical domain degradation (S-helix-II) to assess cartilage damage in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65 Suppl 2:145.
26. Versttappen SM, Poole AR, Ionescu M, et al. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006;8:R31.
27. Cahue S, Sharma L, Dunlop D, et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007;15:819-23.
28. Mullan RH, Matthews C, Bresnihan B, et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 2007;56:2919-28.
29. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor blockade in spondyloarthropathy. Arthritis Rheum 2004;50:2942-53.
30. Fraser A, Fearon U, Billinghurst RC, et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans. Relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003;52:3085-95.
31. Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritis: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994;53:768-72.
32. Maksymowych WP, Landewé R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-53.
33. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-α antibody infliximab. Rheumatology Oxford 2007;46:1450-3.
34. van der Heijde D, Landewe R, Ory P, et al. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:81.